AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial publ
While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in h
Eli Lilly has started dosing patients in the world's first trial for a medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.
Canadian biotech AbCellera has joined forces with Eli Lilly to co-develop antibody products to prevent and treat COVID-19, the disease caused by the novel SARS-Cov-2 coronavirus.
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.